Tenaya Therapeutics Income Statement (2020-2026) | TNYA

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
0.23M
Operating items
Research & Development (Quarter)
10.91M12.94M20.95M24.16M20.88M23.76M25.75M25.61M26.48M23.09M22.86M25.05M22.65M20.35M18.69M21.08M17.37M15.36M14.80M14.84M
Selling, General & Administrative (Quarter)
4.33M5.36M5.21M7.00M7.74M7.54M8.80M8.12M8.63M7.83M8.58M8.71M8.17M6.36M5.96M6.46M6.71M5.57M5.98M5.45M
Operating Expenses (Quarter)
15.24M18.30M26.16M31.15M28.62M31.30M34.55M33.72M35.10M30.92M31.45M33.76M30.82M26.71M24.65M27.54M24.08M20.94M20.77M20.29M
Operating Income (Quarter)
-15.24M-18.30M-26.16M-31.15M-28.62M-31.30M-34.55M-33.72M-35.10M-30.92M-31.45M-33.76M-30.82M-26.71M-24.65M-27.54M-24.08M-20.94M-20.77M-20.07M
EBIT (Quarter)
-15.24M-18.30M-26.16M-31.15M-28.62M-31.30M-34.55M-33.72M-35.10M-30.92M-31.45M-33.76M-30.82M-26.71M-24.65M-27.54M-24.08M-20.94M-20.77M-20.07M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.02M0.07M0.10M0.22M0.60M1.04M1.97M1.84M1.78M1.47M1.45M1.39M1.08M0.81M0.64M0.81M0.66M0.57M0.79M
Other Non Operating Income (Quarter)
0.02M0.01M-0.05M-0.00M0.01M-0.00M0.01M-0.00M0.00M0.04M0.08M-0.00M-0.00M0.00M0.04M-0.02M0.00M0.03M
Non Operating Income (Quarter)
0.03M0.04M-0.05M0.10M0.22M0.60M-0.00M1.99M-0.00M0.00M1.51M1.53M-0.00M1.08M0.00M0.04M-0.02M0.66M0.03M0.79M
Net income details
EBT (Quarter)
-15.21M-18.26M-26.15M-31.06M-28.40M-30.70M-33.52M-31.74M-33.27M-29.14M-29.93M-32.23M-29.43M-25.63M-23.84M-26.86M-23.28M-20.27M-20.18M-19.27M
Profit After Tax (Quarter)
-15.21M-18.26M-26.13M-31.06M-28.40M-30.70M-33.56M-31.74M-33.27M-29.14M-29.95M-32.23M-29.43M-25.63M-23.81M-26.86M-23.28M-20.27M-20.18M-19.27M
Income from Continuing Operations (Quarter)
-15.21M-18.26M-26.15M-31.06M-28.40M-30.70M-33.52M-31.74M-33.27M-29.14M-29.93M-32.23M-29.43M-25.63M-23.84M-26.86M-23.28M-20.27M-20.18M-19.27M
Consolidated Net Income (Quarter)
-15.21M-18.26M-26.15M-31.06M-28.40M-30.70M-33.52M-31.74M-33.27M-29.14M-29.93M-32.23M-29.43M-25.63M-23.84M-26.86M-23.28M-20.27M-20.18M-19.27M
Income towards Parent Company (Quarter)
-15.21M-18.26M-26.15M-31.06M-28.40M-30.70M-33.52M-31.74M-33.27M-29.14M-29.93M-32.23M-29.43M-25.63M-23.84M-26.86M-23.28M-20.27M-20.18M-19.27M
Net Income towards Common Stockholders (Quarter)
-15.21M-18.26M-26.15M-31.06M-28.40M-30.70M-33.52M-31.74M-33.27M-29.14M-29.93M-32.23M-29.43M-25.63M-23.84M-26.86M-23.28M-20.27M-20.18M-19.27M
Additional items
EPS (Basic) (Quarter)
-13.26-0.680.65-0.75-0.69-0.74-0.58-0.43-0.45-0.39-0.40-0.40-0.34-0.30-0.27-0.24-0.14-0.12-0.11-0.09
EPS (Weighted Average and Diluted) (Quarter)
-0.680.65-0.75-0.69-0.74-0.58-0.43-0.45-0.39-0.40-0.40-0.34-0.30-0.27-0.24-0.14-0.12-0.11-0.09
Shares Outstanding (Weighted Average) (Quarter)
1.12M26.90M17.73M41.27M41.30M41.36M44.82M73.10M73.25M73.58M73.79M80.98M83.34M86.16M84.82M109.87M136.48M163.35M152.97M216.88M
Shares Outstanding (Diluted Average) (Quarter)
9.81M17.73M41.27M41.29M41.31M44.82M73.10M73.25M73.58M73.79M80.98M83.34M84.29M84.82M109.87M136.48M163.35M152.97M216.88M
EBITDA (Quarter)
-15.21M-18.29M-26.27M-31.55M-28.50M-30.72M-33.13M-31.48M-33.48M-29.07M-29.78M-32.24M-29.38M-25.49M-23.88M-26.90M-23.27M-20.27M-20.18M-19.27M
Shares Outstanding (Quarter)
1.22M41.28M41.29M41.30M41.36M41.37M66.86M66.87M67.87M68.11M68.33M78.52M78.87M79.22M86.54M162.66M162.98M163.74M216.76M217.00M